PURPOSE: We have previously reported on measuring macular pigment density (MPD) with a scanning laser ophthalmoscope (HRA, Heidelberg Engineering, Heidelberg, Germany). This study war undertaken to evaluate the variation of MPD over a period of 1 year in healthy subjects. METHOD: We used autofluorescence images recorded with a HRA to evaluate MPD with a 2 degrees circle centered on the fovea. Healthy subjects were included in the study and MPD measurements were repeated every 2 months over a period of 1 year. RESULTS: We included a total of 30 healthy subjects aged 19-34 years (mean: 23+/-2 years). Mean MPD at time point 1 was 0.215+/-0.056 density units (DU), at time point 2 0.235+/-0.051 DU, at time point 3 0.218+/-0.055 DU, at time point 4 0.228+/-0.057 DU, at time point 5 0.225+/-0.053 DU, and at time point 6 0.203+/-0.050 DU. The statistical analysis revealed no significant variation of MPD over the follow-up period of 1 year. CONCLUSION: This study demonstrates that MPD shows no variation over a period of 1 year in healthy subjects.
PURPOSE: We have previously reported on measuring macular pigment density (MPD) with a scanning laser ophthalmoscope (HRA, Heidelberg Engineering, Heidelberg, Germany). This study war undertaken to evaluate the variation of MPD over a period of 1 year in healthy subjects. METHOD: We used autofluorescence images recorded with a HRA to evaluate MPD with a 2 degrees circle centered on the fovea. Healthy subjects were included in the study and MPD measurements were repeated every 2 months over a period of 1 year. RESULTS: We included a total of 30 healthy subjects aged 19-34 years (mean: 23+/-2 years). Mean MPD at time point 1 was 0.215+/-0.056 density units (DU), at time point 2 0.235+/-0.051 DU, at time point 3 0.218+/-0.055 DU, at time point 4 0.228+/-0.057 DU, at time point 5 0.225+/-0.053 DU, and at time point 6 0.203+/-0.050 DU. The statistical analysis revealed no significant variation of MPD over the follow-up period of 1 year. CONCLUSION: This study demonstrates that MPD shows no variation over a period of 1 year in healthy subjects.
Authors: Anthony G Robson; Jack D Moreland; Daniel Pauleikhoff; Tony Morrissey; Graham E Holder; Fred W Fitzke; Alan C Bird; Frederik J G M van Kuijk Journal: Vision Res Date: 2003-07 Impact factor: 1.886
Authors: Henrike Wüstemeyer; Andreas Moessner; Cornelia Jahn; Sebastian Wolf Journal: Graefes Arch Clin Exp Ophthalmol Date: 2003-07-17 Impact factor: 3.117
Authors: Tos T J M Berendschot; Jacqueline J M Willemse-Assink; Mieke Bastiaanse; Paulus T V M de Jong; Dirk van Norren Journal: Invest Ophthalmol Vis Sci Date: 2002-06 Impact factor: 4.799
Authors: B R Hammond; E J Johnson; R M Russell; N I Krinsky; K J Yeum; R B Edwards; D M Snodderly Journal: Invest Ophthalmol Vis Sci Date: 1997-08 Impact factor: 4.799